D. E. Shaw & Co., Inc. Atai Life Sciences N.V. Transaction History

D. E. Shaw & Co., Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.04 - $1.55 $112,494 - $167,660	108,168 New	108,168 $152,000
Q4 2022 Feb 14, 2023	SELL	$2.38 - $3.55 $210,089 - $313,369	-88,273 Reduced 83.78%	17,090 $45,000
Q3 2022 Nov 14, 2022	SELL	$3.14 - $4.87 $902,982 - $1.4 Million	-287,574 Reduced 73.19%	105,363 $349,000
Q2 2022 Aug 15, 2022	BUY	$3.03 - $5.32 $523,268 - $918,742	172,696 Added 78.41%	392,937 $1.43 Million
Q1 2022 May 16, 2022	BUY	$4.66 - $7.66 $129,198 - $212,373	27,725 Added 14.4%	220,241 $1.12 Million
Q4 2021 Feb 14, 2022	BUY	$6.82 - $17.8 $1.31 Million - $3.43 Million	192,516 New	192,516 $1.47 Million

12.4M

77.8K

50.3K

Ticker ATAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 165,875,008
Market Cap $197M
Description
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.